EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Comparison of Colonoscopy, Fecal Immunochemical Test, and Risk-Adapted Approach in a Colorectal Cancer Screening Trial (TARGET-C)

Hongda Chen, Jufang Shi, Ming Lu, Yanjie Li, Lingbin Du, Xianzhen Liao, Donghua Wei, Dong Dong, Yi Gao, Chen Zhu, Rongbiao Ying, Weifang Zheng und 17 weitere

Clinical Gastroenterology and Hepatology · 2023-03 · 21 (3) · 808-818

DOI: 10.1016/j.cgh.2022.08.003 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023-03. Verfasst von Hongda Chen und 28 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Hauptthemen laut MEDLINE: Early Detection of Cancer, Colorectal Neoplasms. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: The screening yield and related cost of a risk-adapted screening approach compared with established screening strategies in population-based colorectal cancer (CRC) screening are not clear. METHODS: We randomly allocated 19,373 participants into 1 of the 3 screening arms in a 1:2:2 ratio: (1) one-time colonoscopy (n = 3883); (2) annual fecal immunochemical test (FIT) (n = 7793); (3) annual risk-adapted screening (n = 7697), in which, based on the risk-stratification score, high-risk participants were referred for colonoscopy and low-risk ones were referred for FIT. Three consecutive screening rounds were conducted for both the FIT and the risk-adapted screening arms. Follow-up to trace the health outcome for all the participants was conducted over the 3-year study period. The detection rate of advanced colorectal neoplasia (CRC and advanced precancerous lesions) was the main outcome. The trial was registered in the Chinese Clinical Trial Registry (number: ChiCTR1800015506). RESULTS: In the colonoscopy, FIT, and risk-adapted screening arms over 3 screening rounds, the participation rates were 42.4%, 99.3%, and 89.2%, respectively; the detection rates for advanced neoplasm (intention-to-treat analysis) were 2.76%, 2.17%, and 2.35%, respectively, with an odds ratio (OR)colonoscopy vs FIT of 1.27 (95% confidence interval [CI]: 0.99-1.63; P = .056), an ORcolonoscopy vsrisk-adapted screening of 1.17 (95% CI, 0.91-1.49; P = .218), and an ORrisk-adapted screeningvs FIT of 1.09 (95% CI, 0.88-1.35; P = .438); the numbers of colonoscopies needed to detect 1 advanced neoplasm were 15.4, 7.8, and 10.2, respectively; the costs for detecting 1 advanced neoplasm from a government perspective using package payment format were 6928 Chinese Yuan (CNY) ($1004), 5821 CNY ($844), and 6694 CNY ($970), respectively. CONCLUSIONS: The risk-adapted approach is a feasible and cost-favorable strategy for population-based CRC screening and therefore could complement the well-established one-time colonoscopy and annual repeated FIT screening strategies. (Chinese Clinical Trial Registry; ChiCTR1800015506).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Early Detection of CancerColorectal NeoplasmsHumansColonoscopyRisk FactorsMass ScreeningOccult BloodFeces

Stichwörter der Autor:innen

ColonoscopyColorectal Cancer ScreeningFecal Immunochemical TestPersonalized ScreeningRisk Stratification

Autor:innen und Institutionen

  • Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Cancer Prevention, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences/Cancer Hospital of University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Hangzhou, China.
  • Department of Cancer Prevention, Hunan Cancer Hospital, Changsha, China.
  • Department of Cancer Prevention, Anhui Provincial Cancer Hospital, Hefei, China.
  • Office of Cancer Prevention and Treatment, Xuzhou Cancer Hospital, Xuzhou, China.

Zitieren

APA

Chen, H., Shi, J., Lu, M., Li, Y., Du, L., Liao, X., Wei, D., Dong, D., Gao, Y., Zhu, C., Ying, R., Zheng, W., Yan, S., Xiao, H., Zhang, J., Kong, Y., Li, F., Zou, S., Liu, C., …, & Dai, M. (2023). Comparison of Colonoscopy, Fecal Immunochemical Test, and Risk-Adapted Approach in a Colorectal Cancer Screening Trial (TARGET-C). Clinical Gastroenterology and Hepatology, 21(3), 808-818. https://doi.org/10.1016/j.cgh.2022.08.003

Vancouver

Chen H, Shi J, Lu M, Li Y, Du L, Liao X, et al. Comparison of Colonoscopy, Fecal Immunochemical Test, and Risk-Adapted Approach in a Colorectal Cancer Screening Trial (TARGET-C). Clinical Gastroenterology and Hepatology. 2023;21(3):808-818. doi:10.1016/j.cgh.2022.08.003

BibTeX
@article{Chen2023,
  author = {Chen, Hongda and Shi, Jufang and Lu, Ming and Li, Yanjie and Du, Lingbin and Liao, Xianzhen and Wei, Donghua and Dong, Dong and Gao, Yi and Zhu, Chen and Ying, Rongbiao and Zheng, Weifang and Yan, Shipeng and Xiao, Haifan and Zhang, Juan and Kong, Yunxin and Li, Furong and Zou, Shuangmei and Liu, Chengcheng and Wang, Hong and Zhang, Yuhan and Lu, Bin and Luo, Chenyu and Cai, Jie and Tian, Jianbo and Miao, Xiaoping and Ding, Kefeng and Brenner, Hermann and Dai, Min},
  title = {Comparison of Colonoscopy, Fecal Immunochemical Test, and Risk-Adapted Approach in a Colorectal Cancer Screening Trial (TARGET-C)},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2023},
  volume = {21},
  number = {3},
  pages = {808--818},
  doi = {10.1016/j.cgh.2022.08.003}
}
Kostenlos starten →